Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
Three IPOs and one SPAC debuted this past week, while three IPOs submitted initial filings.Phase 1 oncology biotech Boundless Bio (BOLD) raised $100 million at a $396 million market cap. The company is focused on developing therapies for oncogene amplified...read more
Boundless Bio, a Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors, raised $100 million by offering 6.3 million shares at $16, within the range of $15 to $17. Boundless Bio is focused on developing therapies for oncogene amplified...read more
Three listings are currently scheduled for the week ahead, although other issuers may join the calendar throughout the week.Phase 1 oncology biotech Boundless Bio (BOLD) plans to raise $100 million at a $396 million market cap. The company is focused on...read more
Biotech bust: 2024 biotech IPOs average a -52% return
Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more
US IPO Weekly Recap: Biotech leads short 3 IPO week
Three IPOs and one SPAC debuted this past week, while three IPOs submitted initial filings.Phase 1 oncology biotech Boundless Bio (BOLD) raised $100 million at a $396 million market cap. The company is focused on developing therapies for oncogene amplified...read more
Oncology biotech Boundless Bio prices IPO at $16 midpoint
Boundless Bio, a Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors, raised $100 million by offering 6.3 million shares at $16, within the range of $15 to $17. Boundless Bio is focused on developing therapies for oncogene amplified...read more
US IPO Week Ahead: Oncology biotech leads 3 IPO week
Three listings are currently scheduled for the week ahead, although other issuers may join the calendar throughout the week.Phase 1 oncology biotech Boundless Bio (BOLD) plans to raise $100 million at a $396 million market cap. The company is focused on...read more